Efficacy and Safety of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Document Type
Abstract
Publication Date
June 2017
Journal Title
Journal of the American Academy of Dermatology
Department
Dermatology
Recommended Citation
Gottlieb, A., Deodhar, A., Boehncke, W., Dong, B., Wang, Y., Barchuk, W., & Hsia, E. (2017). Efficacy and Safety of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients With Active Psoriatic Arthritis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Dermatology, 76 (6 Suppl. 1), AB111. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/43
COinS
